Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals puts another potential treatment in the pot

GW Pharmaceuticals puts another potential treatment in the pot

Cannabis-based drug maker GW Pharmaceuticals (LON:GWP) has potentially added a new treatment to its development pipeline following a positive outcome in a university research programme.

The research carried out at Reading University, and part funded by GW, has demonstrated for the first time that a previously unstudied chemical present in cannabis, called cannabidivarin (or CBDV)  could lead to more effective treatment for people with epilepsy.

In the study the chemical strongly suppressed seizures, GW said.

GW already has already developed and commercialised a cannabis based treatment – in the form of a spray – for people suffering from multiple sclerosis. And it continues to explore other potential treatments.

"These results further underscore the potential of naturally-derived cannabinoids as medicines to treat a broad range of diseases,” said Dr Stephen Wright, GW Pharmaceuticals’ director of research and development. 

“GW has established a track record of discovering and commercialising such compounds with Sativex®now on the market for treating spasticity associated with multiple sclerosis and in late stage development for the treatment of cancer pain. 

“Our research into CBDV has consistently produced highly promising results demonstrating its potential as a novel anticonvulsant and GW hopes during 2013 to advance CBDV into human clinical trials."

 

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
x-ray
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use